---
title: "CSPC PHARMA: The inhalation powder of nintedanib ethane sulfonate has received clinical trial approval in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271329023.md"
description: "CSPC PHARMA announced that its developed inhalation powder of nintedanib mesylate has been approved by the National Medical Products Administration of China for clinical trials. This is the first inhalation formulation approved in the country for the treatment of pulmonary fibrosis, offering advantages such as increased lung exposure and improved lung function. The product can achieve equivalent efficacy at an oral dose of 1/200, and has good safety. The clinical indication is idiopathic pulmonary fibrosis, and it also has the potential for the treatment of other lung diseases in the future"
datetime: "2026-01-02T11:50:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271329023.md)
  - [en](https://longbridge.com/en/news/271329023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271329023.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271329023.md) | [繁體中文](https://longbridge.com/zh-HK/news/271329023.md)


# CSPC PHARMA: The inhalation powder of nintedanib ethane sulfonate has received clinical trial approval in China

According to the announcement from CSPC PHARMA (01093), the inhalation powder of Nintedanib Ethanesulfonate developed by the group has been approved by the National Medical Products Administration of China for clinical trials in China.

This product is the first inhalation formulation approved for clinical use in the treatment of pulmonary fibrosis in the country. Nintedanib Ethanesulfonate is a multi-tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis (IPF), with the currently marketed formulation being oral soft capsules. Compared to oral formulations, this product has significant advantages, including significantly increased lung exposure, marked improvement in lung function, reduced systemic exposure, and significantly reduced gastrointestinal side effects. Preclinical studies have shown that this product can achieve equivalent efficacy at an oral dose of 1/200, and it has good safety and effectiveness.

The approved clinical indication is idiopathic pulmonary fibrosis. In addition, this product also has the potential for treating systemic sclerosis-related interstitial lung disease (SSc-ILD) and progressive pulmonary fibrosis (PPF). This product is an important achievement of the group's inhalation technology platform, and its approval for clinical trials lays a solid foundation for the development of subsequent inhalation formulations in the pipeline

### Related Stocks

- [CSPC PHARMA (01093.HK)](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/en/news/280415449.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/en/news/280502605.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md)
- [ZAWYA: NYU Abu Dhabi and University of Denver Researchers identify promising small molecule inhibitor of brain disorders like parkinson’s disease](https://longbridge.com/en/news/281500635.md)
- [China's detentions of Panama-flagged vessels raise concerns, Rubio says](https://longbridge.com/en/news/281541796.md)